CA-WETA-DIGITAL
17.12.2020 18:17:18 CET | Business Wire | Press release
Weta Digital, one of the world’s premiere visual effects facilities and parent company of Weta Animated, has announced the addition of industry leaders Tom Staggs, Jeff Huber and Ken Kamins to its Board of Directors. The appointment of Staggs, Huber and Kamins reflect the continued growth and innovation of the company, which is also opening offices in Los Angeles and San Francisco.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201217005350/en/
“Tom, Jeff and Ken are extraordinary additions to the board of Weta Digital,” said Prem Akkaraju, Global CEO of Weta Digital. “They have established best practices at the highest levels of company management, in entertainment and digital technology. Their combined business acumen and collective depth of experience perfectly positions Weta Digital for exponential growth. Opening offices in Los Angeles and San Francisco enables storytellers to tap Weta’s production pipeline and work with concept designers, animation supervisors and other key creatives, in both the US and New Zealand. Weta Digital’s expansion comes at a time when much of the film industry is experiencing extraordinary uncertainty as we grapple with the ongoing impact of Covid-19. We’re extremely fortunate that New Zealand got in front of the curve early - it’s one of the few places in the world that has managed community transmission, where you can make a film safely, without the restrictive protocols of other markets.”
Tom Staggs brings more than 26-years of experience at The Walt Disney Company, including 18 years of C-suite experience with the company. He was most recently Disney’s Chief Operating Officer, having previously served for five years as Chairman of Disney Parks and Resorts Worldwide and for nearly 12 years as Disney’s Chief Financial Officer. During his time at Disney, Staggs helped shape Disney’s strategic, financial, operational, creative and brand management strategies across every segment of the company and helped drive many of Disney’s most important initiatives including the acquisitions of Cap Cities/ABC, Pixar and Marvel. Since departing Disney in late 2016, Staggs has focused on developing several new business ventures across a variety of fields. He is a board member and advisor to a number of private companies, and also serves on the board of directors of music streaming service Spotify. Before joining Disney, Staggs was an investment banker at Morgan Stanley and Dain Bosworth.
“I have long admired Peter Jackson and Fran Walsh’s filmmaking talents and Weta Digital’s accomplishments in animation and visual effects. Weta Digital’s rare combination of creative talent and technology gives them a unique ability to succeed in high-end animation production,” said Staggs. “I look forward to working with Peter, Fran, Prem and the entire Weta Digital team on the animation business and further global expansion.”
Jeff Huber is the former Founding CEO and Vice Chairman of GRAIL and previously a Senior Vice President at Google. Having spent over 13 years at Google, Huber co-founded the company’s life sciences efforts in Google X and led development and scaling for Google Maps, Google Apps and Google Ads. During his tenure as an executive at Google, Jeff oversaw 50x growth in revenues (from $1 billion to >$50 billion) and organization (1,000 to >50,000 employees), and managed a $5 billion P&L and large distributed teams (5,000+ direct-line employees). Prior to Google, Huber served as Vice President of Architecture and Systems Development at eBay and Senior Vice President of Engineering at Excite@Home, where he led consumer product and infrastructure development.
"Weta Digital is known around the world for its astounding visual effects and inventive storytelling. This amazing artistry is driven by groundbreaking technology and non-stop innovation,” said Huber. “The research and development teams at Weta Digital have consistently produced magic and raised the bar as to what is possible. I look forward to the adventures ahead with Peter, Fran, Prem and the entire Weta Digital Team, growing the company in scale and technology excellence to create the next generation of culture-defining stories and experiences."
Ken Kamins is the Founder and CEO of Key Creatives, a management-production company. He has represented Peter Jackson and Fran Walsh since 1992, and his Executive Producer credits include The Hobbit Trilogy , District 9 , and The Adventures of Tintin: The Secret of the Unicorn. Prior to his current position, he served as Executive Vice President of the talent agency, International Creative Management; and before that, as Executive Vice President of RCA/Columbia Pictures Home Entertainment.
“I’ve had a front row seat for the entire growth curve of Weta Digital, from its beginnings in 1993 when the company consisted of just one computer and one artist creating the digital effects in “Heavenly Creatures”, through to this moment,” said Kamins. “Weta Digital was designed by Peter and Fran to be a creative haven for filmmakers - a place where they could let their imaginations run wild. No idea was too crazy or too difficult to try. In collaboration with the many great artists Weta has had the privilege to work with, Joe Letteri, David Conley and their teams have consistently pushed the boundaries of imaginative storytelling.”
Staggs, Huber and Kamins join Weta Digital board members Peter Jackson, Fran Walsh, Sean Parker, Joe Letteri and CEO Prem Akkaraju.
ABOUT WETA DIGITAL:
Weta Digital is the standard-bearer for creativity and innovation in visual effects and animation, attracting talent, partners, and clients that seek to push what is possible in pursuit of their artistic vision. Weta’s proprietary pipeline continues to evolve and provide artists with the tools they need to create their best work. Based in Wellington, New Zealand, Weta Digital is the largest single-site VFX studio in the world drawing artists from over 40 countries. They are some of the most creative and ambitious artists, engineers, and executives in entertainment and their work has earned six visual effects Academy Awards, ten Academy Sci-Tech Awards and six visual effects BAFTA Awards in addition to the 34 Visual Effects Society Awards awarded to them by their peers. Ground-breaking, performance-driven animated characters from Gollum to Caesar, and worlds from Middle-earth to Pandora, are regarded as some of the best visual effects ever to appear on screen.
For more information:
Corporate: www.wetastudios.com
Weta Digital: www.wetafx.co.nz
Follow: @weta_digital
View source version on businesswire.com: https://www.businesswire.com/news/home/20201217005350/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
